- Home
- PD vs PTGX Comparison
PD vs PTGX Comparison
Compare PD & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PD | PTGX |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.9M | 5.2B |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PD | PTGX |
|---|---|---|
| Price | $6.58 | $102.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $12.63 | ★ $107.38 |
| AVG Volume (30 Days) | ★ 2.8M | 826.9K |
| Earning Date | 03-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 416.95 | N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | ★ $492,546,000.00 | N/A |
| Revenue This Year | $3.58 | $873.97 |
| Revenue Next Year | $2.88 | N/A |
| P/E Ratio | $3.53 | ★ N/A |
| Revenue Growth | ★ 5.36 | N/A |
| 52 Week Low | $5.92 | $39.60 |
| 52 Week High | $17.45 | $107.84 |
Technical Indicators
Market Signals| Indicator | PD | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 59.82 |
| Support Level | $6.08 | $76.63 |
| Resistance Level | $8.06 | N/A |
| Average True Range (ATR) | 0.32 | 4.71 |
| MACD | 0.07 | -0.12 |
| Stochastic Oscillator | 51.76 | 70.10 |
Price Performance
Historical ComparisonAbout PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.